X
[{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Scenic Biotech"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$50.0 million","newsHeadline":"ProQR Announces Axiomer\u00ae RNA Editing Licensing and Research Collaboration with Lilly","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ProQR Therapeutics"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$115.0 million","newsHeadline":"ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ProQR Therapeutics"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Scenic Biotech"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Both companies, aim to identify small molecule drugs to treat Niemann Pick Type C (NP-C), a rare lipid storage disorder that affects lipid metabolism, a second undisclosed program to treat a severe heritable metabolic syndrome, and Barth syndrome program.
Lead Product(s):
Undisclosed
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Barth Syndrome Foundation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
March 30, 2022
Details:
This collaboration with Lilly, is an important validation for Axiomer® RNA editing platform of ProQR, which enables the editing of single nucleotides in RNA in a highly targeted and specific manner.
Lead Product(s):
Editing Oligonucleotides
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Eli Lilly
Deal Size: $1,300.0 million
Upfront Cash: $50.0 million
Deal Type: Collaboration
September 08, 2021
Details:
Under the terms of the agreement, Yarrow Biotechnology, a company newly created by RTW, has in-licensed rights to ProQR’s antisense oligonucleotide technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target.
Lead Product(s):
Antisense Oligonucleotide Therapy
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Yarrow Biotechnology
Deal Size: Undisclosed
Upfront Cash: $115.0 million
Deal Type: Collaboration
May 04, 2021
Details:
Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.
Lead Product(s):
Undisclosed
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Genentech
Deal Size: $375.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
September 21, 2020